Vasomotor Symptoms of Menopause Treatment Market Report

Global Vasomotor Symptoms of Menopause Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 03, 2022
  • PAGES：176
  • REPORT CODE：GMM795007
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Vasomotor Symptoms of Menopause Treatment market report explains the definition, types, applications, major countries, and major players of the Vasomotor Symptoms of Menopause Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • MenoGeniX Inc

    • TherapeuticsMD Inc

    • EndoCeutics Inc

    • Mithra Pharmaceuticals SA

    • Pivot Pharmaceuticals Inc

    • Pherin Pharmaceuticals Inc

    • Euroscreen SA

    • Amgen Inc

    • Radius Health Inc

    By Type:

    • Estetrol

    • Fezolinetant

    • FP-101

    • HBN-2

    • Others

    By End-User:

    • Hospital

    • Homecare

    • Clinic

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Vasomotor Symptoms of Menopause Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Vasomotor Symptoms of Menopause Treatment Outlook to 2028- Original Forecasts

    • 2.2 Vasomotor Symptoms of Menopause Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Vasomotor Symptoms of Menopause Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Vasomotor Symptoms of Menopause Treatment Market- Recent Developments

    • 6.1 Vasomotor Symptoms of Menopause Treatment Market News and Developments

    • 6.2 Vasomotor Symptoms of Menopause Treatment Market Deals Landscape

    7 Vasomotor Symptoms of Menopause Treatment Raw Materials and Cost Structure Analysis

    • 7.1 Vasomotor Symptoms of Menopause Treatment Key Raw Materials

    • 7.2 Vasomotor Symptoms of Menopause Treatment Price Trend of Key Raw Materials

    • 7.3 Vasomotor Symptoms of Menopause Treatment Key Suppliers of Raw Materials

    • 7.4 Vasomotor Symptoms of Menopause Treatment Market Concentration Rate of Raw Materials

    • 7.5 Vasomotor Symptoms of Menopause Treatment Cost Structure Analysis

      • 7.5.1 Vasomotor Symptoms of Menopause Treatment Raw Materials Analysis

      • 7.5.2 Vasomotor Symptoms of Menopause Treatment Labor Cost Analysis

      • 7.5.3 Vasomotor Symptoms of Menopause Treatment Manufacturing Expenses Analysis

    8 Global Vasomotor Symptoms of Menopause Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Vasomotor Symptoms of Menopause Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Vasomotor Symptoms of Menopause Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global Vasomotor Symptoms of Menopause Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Estetrol Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Fezolinetant Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global FP-101 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global HBN-2 Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Homecare Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Clinic Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Vasomotor Symptoms of Menopause Treatment Market Analysis and Outlook till 2022

    • 10.1 Global Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.2.2 Canada Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.2.3 Mexico Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.2 UK Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.3 Spain Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.4 Belgium Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.5 France Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.6 Italy Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.7 Denmark Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.8 Finland Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.9 Norway Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.10 Sweden Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.11 Poland Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.12 Russia Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.3.13 Turkey Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.2 Japan Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.3 India Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.4 South Korea Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.8 Thailand Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.9 Singapore Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.11 Philippines Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.5.2 Colombia Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.5.3 Chile Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.5.4 Argentina Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.5.6 Peru Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.6.3 Oman Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.6.4 Qatar Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.7.2 South Africa Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.7.3 Egypt Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.7.4 Algeria Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand Vasomotor Symptoms of Menopause Treatment Consumption (2017-2022)

    11 Global Vasomotor Symptoms of Menopause Treatment Competitive Analysis

    • 11.1 MenoGeniX Inc

      • 11.1.1 MenoGeniX Inc Company Details

      • 11.1.2 MenoGeniX Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 MenoGeniX Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

      • 11.1.4 MenoGeniX Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 TherapeuticsMD Inc

      • 11.2.1 TherapeuticsMD Inc Company Details

      • 11.2.2 TherapeuticsMD Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 TherapeuticsMD Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

      • 11.2.4 TherapeuticsMD Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 EndoCeutics Inc

      • 11.3.1 EndoCeutics Inc Company Details

      • 11.3.2 EndoCeutics Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 EndoCeutics Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

      • 11.3.4 EndoCeutics Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Mithra Pharmaceuticals SA

      • 11.4.1 Mithra Pharmaceuticals SA Company Details

      • 11.4.2 Mithra Pharmaceuticals SA Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Mithra Pharmaceuticals SA Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

      • 11.4.4 Mithra Pharmaceuticals SA Vasomotor Symptoms of Menopause Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Pivot Pharmaceuticals Inc

      • 11.5.1 Pivot Pharmaceuticals Inc Company Details

      • 11.5.2 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

      • 11.5.4 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Pherin Pharmaceuticals Inc

      • 11.6.1 Pherin Pharmaceuticals Inc Company Details

      • 11.6.2 Pherin Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Pherin Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

      • 11.6.4 Pherin Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Euroscreen SA

      • 11.7.1 Euroscreen SA Company Details

      • 11.7.2 Euroscreen SA Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Euroscreen SA Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

      • 11.7.4 Euroscreen SA Vasomotor Symptoms of Menopause Treatment Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Amgen Inc

      • 11.8.1 Amgen Inc Company Details

      • 11.8.2 Amgen Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Amgen Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

      • 11.8.4 Amgen Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Radius Health Inc

      • 11.9.1 Radius Health Inc Company Details

      • 11.9.2 Radius Health Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Radius Health Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

      • 11.9.4 Radius Health Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    12 Global Vasomotor Symptoms of Menopause Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Estetrol Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Fezolinetant Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global FP-101 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global HBN-2 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Homecare Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Vasomotor Symptoms of Menopause Treatment Market Analysis and Outlook to 2028

    • 13.1 Global Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Vasomotor Symptoms of Menopause Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Vasomotor Symptoms of Menopause Treatment

    • Figure of Vasomotor Symptoms of Menopause Treatment Picture

    • Table Global Vasomotor Symptoms of Menopause Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Vasomotor Symptoms of Menopause Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Estetrol Consumption and Growth Rate (2017-2022)

    • Figure Global Fezolinetant Consumption and Growth Rate (2017-2022)

    • Figure Global FP-101 Consumption and Growth Rate (2017-2022)

    • Figure Global HBN-2 Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Homecare Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Vasomotor Symptoms of Menopause Treatment Consumption by Country (2017-2022)

    • Table North America Vasomotor Symptoms of Menopause Treatment Consumption by Country (2017-2022)

    • Figure United States Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Vasomotor Symptoms of Menopause Treatment Consumption by Country (2017-2022)

    • Figure Germany Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure France Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC Vasomotor Symptoms of Menopause Treatment Consumption by Country (2017-2022)

    • Figure China Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Table South America Vasomotor Symptoms of Menopause Treatment Consumption by Country (2017-2022)

    • Figure Brazil Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC Vasomotor Symptoms of Menopause Treatment Consumption by Country (2017-2022)

    • Figure Bahrain Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa Vasomotor Symptoms of Menopause Treatment Consumption by Country (2017-2022)

    • Figure Nigeria Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania Vasomotor Symptoms of Menopause Treatment Consumption by Country (2017-2022)

    • Figure Australia Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Vasomotor Symptoms of Menopause Treatment Consumption and Growth Rate (2017-2022)

    • Table MenoGeniX Inc Company Details

    • Table MenoGeniX Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table MenoGeniX Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

    • Table MenoGeniX Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

    • Table TherapeuticsMD Inc Company Details

    • Table TherapeuticsMD Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table TherapeuticsMD Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

    • Table TherapeuticsMD Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

    • Table EndoCeutics Inc Company Details

    • Table EndoCeutics Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table EndoCeutics Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

    • Table EndoCeutics Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

    • Table Mithra Pharmaceuticals SA Company Details

    • Table Mithra Pharmaceuticals SA Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mithra Pharmaceuticals SA Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

    • Table Mithra Pharmaceuticals SA Vasomotor Symptoms of Menopause Treatment Product Portfolio

    • Table Pivot Pharmaceuticals Inc Company Details

    • Table Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

    • Table Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

    • Table Pherin Pharmaceuticals Inc Company Details

    • Table Pherin Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pherin Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

    • Table Pherin Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

    • Table Euroscreen SA Company Details

    • Table Euroscreen SA Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Euroscreen SA Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

    • Table Euroscreen SA Vasomotor Symptoms of Menopause Treatment Product Portfolio

    • Table Amgen Inc Company Details

    • Table Amgen Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

    • Table Amgen Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

    • Table Radius Health Inc Company Details

    • Table Radius Health Inc Vasomotor Symptoms of Menopause Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Radius Health Inc Vasomotor Symptoms of Menopause Treatment Main Business and Markets Served

    • Table Radius Health Inc Vasomotor Symptoms of Menopause Treatment Product Portfolio

    • Figure Global Estetrol Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Fezolinetant Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global FP-101 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global HBN-2 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Homecare Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Vasomotor Symptoms of Menopause Treatment Consumption Forecast by Country (2022-2028)

    • Table North America Vasomotor Symptoms of Menopause Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Vasomotor Symptoms of Menopause Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Vasomotor Symptoms of Menopause Treatment Consumption Forecast by Country (2022-2028)

    • Figure China Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Vasomotor Symptoms of Menopause Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Vasomotor Symptoms of Menopause Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Vasomotor Symptoms of Menopause Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Vasomotor Symptoms of Menopause Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Vasomotor Symptoms of Menopause Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US